PubMed Health⌕ Search

PubMed · 11088157

Passive particle transport in three-vortex flow

Abstract

We study transport of tracer particles in a two-dimensional incompressible inviscid flow produced by three point vortices of equal strength. Time dependence of the flow caused by vortex motion gives rise to chaotic tracer trajectories, which fill parts of the flow plane referred to as mixing regions. For general vortex positions, a large connected mixing region (chaotic sea) is formed around vortices. It comprises a number of coherent fluid patches (islands), which do not mix with the rest of the chaotic sea, inside them particle motion is predominantly regular; three near-circular islands surrounding vortices are distinguished by their robust nature. Tracers in the chaotic sea rotate around the center of vorticity in an irregular way. Their trajectories are intermittent, long flights of almost regular motion are caused by trappings in the boundary regions of regular islands. The statistics of tracer rotation exhibits anomalous features, such as faster than linear growth of tracer ensemble variance and asymmetric probability distribution with long power tails. Exponent of the variance growth power law is different for different time ranges. Central part of the tracer distribution and its low (noninteger) moments evolve in a self-similar way, characterized by an exponent, which is different from that of the variance, and contrary to the latter is constant in time. Algebraic tails of the tracer distribution, controlling the behavior of the variance, are responsible for this effect. Long correlations in tracer motion lead to non-Poissonian distribution of Poincare recurrences in the mixing region. Analysis of long recurrences proves, that they are caused by tracer trappings inside boundary layers of islands of regular motion, which always exist inside the mixing region. Statistics of Poincare recurrences and trapping times exhibit power-law decay, indicating absence of a characteristic relaxation time. Values of the decay exponent for recurrences and for escape from the analyzed traps are very close to each other; long correlations are not dominated by a single trap, but are a cumulative effect of all of them, relative importance of a trap is determined by its size, and by its rotation frequency with respect to the background.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Kuznetsov, GM Zaslavsky. 2000. Passive particle transport in three-vortex flow. https://doi.org/10.1103/physreve.61.3777

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗